Cite
HARVARD Citation
Lu, S. et al. (n.d.). The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy. Leukemia & lymphoma. 56 (4), pp. 1027-1032. [Online].